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Summary 
To assess the effects of interferon 3/(IFN-y) on very primitive hematopoietic progenitor cells, 
CD342+CD38-  human bone marrow cells were isolated and cultured in a two-stage culture 
system, consisting of a primary liquid culture phase followed by a secondary semisolid colony 
assay. CD342+CD38 -  cells needed at least the presence of interleukin 3 (IL-3) and kit ligand 
(KL) together with either IL-1,  IL-6, or granulocyte-colony-stimulating factor (G-CSF) in the 
primary liquid phase in order to proliferate and differentiate into secondary colony-forming cells 
(CFC). Addition of IFN-7 to the primary liquid cultures inhibited cell proliferation and generation 
of secondary CFC in a dose-dependent way. This was a direct effect since it was also seen in primary 
single cell cultures of CD342 +  CD38-  cells. The proliferation of more mature CD34 +  CD38 + 
cells, however, was not inhibited by IFN-7,  demonstrating for the first time that IFN-7 is a 
specific and direct hematopoietic stem cell inhibitor.  IFN-  7,  moreover, preserves the viability 
of CD342+CD38 -  cells in the absence of other cytokines. IFN-  7  could, therefore, play a role 
in the protection of the stem cell compartment from exhaustion in situations of hematopoietic 
stress  and may be useful as stem cell protecting agent against chemotherapy for cancer. 
D 
ifferentiation and proliferation of primitive hematopoi- 
etic progenitor cells  is  tightly regulated by colony- 
stimulating factors (CSF) and by cytokines that act in syn- 
ergy with CSF to stimulate the development of progenitor 
cells into mature cells (1). Recently several reports have demon- 
strated direct stimulatory effects of IFN-7 on hematopoietic 
progenitor  cells  in  synergy  with  other  hemoregulatory 
cytokines such as IL-3  (2-4),  GM-CSF (2-4),  c-kit ligand 
(KL) (5) and the combination of IL-3 and erythropoietin (epo) 
(6).  Moreover, IFN-7 stimulates the expansion of progen- 
itor cells induced by IL-3, IL-6, IL-1, epo, and KL (7) and 
the growth of acute myeloblastic leukemia cells supported 
by IL-3 (6).  The growth of G-CSF-responsive granulocytic 
progenitors however is directly inhibited by IFN-7 (4). The 
direct effects of IFN-7 on very primitive progenitor and stem 
cells, however, have not been reported thus far. Very primi- 
tive human hematopoietic progenitor and stem cells are charac- 
terized by a high expression of CD34 and the absence of CD38 
expression (CD342+ CD38-  cells). Upon differentiation and 
lineage commitment, the expression of CD38 increases while 
the expression of CD34 decreases (CD34 +  CD38 + cells) (8, 
9). To study the effects of IFN-7 on the early stages of the 
development of these very primitive human progenitor cells, 
we used a precolony-forming cell (pre-CFC) assay (10,  11) 
where the effects of the presence of IFN-'y in primary cul- 
tures of CD342+CD38 -  cells on the output of secondary 
CFCs was studied. Here we report that IFN-7 is a potent 
and selective direct inhibitor of CD342+CD38 -  and not of 
CD34+CD38 +  cells.  These findings indicate that  IFN-7 
may play a role in protecting the stem cell compartment from 
exhaustion in situations of hematopoietic stress and that IFN-7 
could be useful for the specific protection of hematopoietic 
stem cells against chemotherapy for cancer. 
Materials and Methods 
Bone Marrow Cells.  Bone marrow samples were aspirated by 
sternal puncture from hematologically normal patients undergoing 
cardiac surgery, after informed consent according to the regula- 
tions of the Ethics Committee of the University of Antwerp, in 
tubes containing 2 ml IMDM (GIBCO, Paisley, UK) and 5 U/ml 
preservative free heparin (Novo Industries, Bagsvaerd, Denmark). 
Cells were separated on a lymphocyte separation medium (LSM; 
Boehringer Mannheim GmbH, Penzberg, Germany) density gra- 
dient and washed twice. Remaining RBC were lysed using an 
NH4C1 containing lysing solution. 
Cytokines and Monoclonal Antibodies.  Supernatant of the 43A1 
hybridoma (IgG3, kindly donated by Dr. H. J. B/ihring, Univer- 
sity of T/ibingen, Tiibingen, Germany) (12) was used as a source 
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ulin F(ab')5 fragments (RAM) were purchased from Dako (Glos- 
trup,  Denmark).  PE-conjugated anti-CD38  (IgG1) antibodies as 
well as isotype-specific control antibodies were purchased from 
Becton Dickinson  (Erembodegem,  Belgium).  Monoclonal neu- 
tralizing  anti-IFN-'t antibody (clone GZ-4, IgG1K) and isotype- 
matched irrelevant control antibody (antidigoxigenin, IgG1K) were 
kindly donated by Dr. M. Kubbies (Boehringer Mannheim GmbH). 
Recombinant  human  IFN-3, (specific activity 2  x  107 U/mg), 
II.6 (108 U/mg), and I1.1 (5  x  107 U/mg) were obtained from 
Boehringer Mannheim GmbH. Recombinant human G-CSF, GM- 
CSF, and 11,3 were a kind gift of Dr. S. C. Clark (Genetics Insti- 
tute, Cambridge, MA), while recombinant human KL was kindly 
donated by Dr. M. Kubbies. Erythropoietin (epo) was purchased 
from Cilag (105 U/rag; Brussels, Belgium). 
Cell Sorting.  Bone marrow cells were incubated at 107 cells/ml 
with 43A1 supernatant in a 1:10  dilution for 20. min at 4~  washed 
twice in IMDM containing 2% FCS, incubated with fluorescei- 
nated RAM (1/50 dilution) for 20 min at 4~  After washing the 
cells twice in IMDM  +  2% FCS, they were sorted on a FACStar 
Plus  |  cell sorter (Becton Dickinson) equipped with an air-cooled 
argon ion laser (ILT model 5500A; Ion Laser Technology, Salt Lake 
City, UT). Cells with a low to medium forward scatter and a low 
side scatter, a highly positive green (CD34) fluorescence, and an 
orange (CD38) fluorescence signal lower than the mean fluores- 
cence of cells labeled with control antibody +  2 standard devia- 
tions were retained as CD342+CD38 - cells; cells with an orange 
fluorescence above this threshold were retained as CD34 §  CD38 § 
ceils. Purities were always >95%. 
Pre-CFU Assay.  Primary  liquid cultures  were performed in 
duplicate in 96-weU  fiat-bottomed plates at 100 cells/well in IMDM, 
10% FCS, and combinations of the following recombinant human 
cytokines: 100 ng/ml 11,1, 200 U/ml 11,6, 100 ng/ml G-CSF, 30 
U/ml I1,3, 100 ng/ml KL, and varying concentrations of IFN-3,. 
After  14 d of primary culture,  the number of cells in each well 
was counted using an inverted microscope at 250x magnification, 
after which the cells were harvested, washed three times in IMDM 
+  10%  FCS, and plated in secondary methylcellulose cultures 
(0.9%)  supplemented with 20% FCS, 1% BSA, 10 -5 M 2-mer- 
captoethanol, 30 U/ml I1,3, 100 ng/ml G-CSF, 100 ng/ml GM-CSF, 
and 2 U/ml epo, which were found to be optimal concentrations 
for colony formation in preliminary experiments. These cultures 
were microscopically scored for colony formation after 14 and after 
21 d of culture at 37~  in 7.5%  O5 and 5% CO2 in a fully hu- 
midified incubator. 
To ascertain that  the effects of IFN-3, in  these experiments 
were direct, the same experiments were performed at a single cell 
level. CD342+CD38 -  cells were sorted at  1 cell/well in 96-well 
V-bottomed plates (two plates per cytokine combination). In test 
sorts using fluorescent microbeads, on average <2% of the wells 
contained no beads and no wells were detected which contained 
more than one bead. Each well contained 100/~1 of  culture medium 
consisting of IMDM, 10% FCS, 11,1, 11,6, I1,3, and KL (concen- 
trations as in the primary cultures described above) and either no 
IFN-'y or IFN-  3' at 105 U/ml. After 14 d of culture (37~  7.5% 
05, 5% CO2 in a fully humidified incubator), the number of wells 
where growth had occurred (primary colonies) was scored using 
an inverted microscope,  the primary colonies  were harvested, washed 
four times, and individually plated in secondary methylcellulose 
cultures as described above. Secondary colony formation was as- 
sessed after 14 and 21 d of secondary culture. Parallel experiments 
were performed using CD34+CD38 + cells (which constitute the 
remainder of the CD34 + cells). 
In a number of experiments, the cells were first cultured in the 
presence or absence of IFN-3' without any other cytokines for 4 d 
in 96-weU flat-bottomed  plates, after which the number of  remaining 
cells was counted by phase contrast microscopy  (250x magnification). 
Shrunken, dull-appearing cells with a ruffled cell membrane were 
considered to be dead and were not counted. The cells were then 
harvested, washed, and cultured in liquid culture medium for 14 d 
in the presence of KL (100 ng/ml), 11,1 (100 ng/ml), IL-6 (200 
U/ml), and I1,3 (30 U/ml). After 14 d of culture the cells were 
harvested, washed, and plated out in secondary  methylcellulose  cul- 
tures as described above. 
Statistics.  In all experiments,  the Student's  t test  for paired 
samples was used. 
Results 
Cytokine  Requirements  of  CD342+CD38 -  Cells.  The 
CD342+CD38 -  fraction comprises "~,0.01-0.05%  of human 
bone  marrow  cells  and  1-5%  of the  CD34 +  cells  (not 
shown).  These cells hardly form any colonies when plated 
directly in semisolid methylcellulose cultures in the presence 
of combinations of CSF such as IL-3, GM-CSF, G-CSF, and 
epo (cloning efficiency <2%, results not shown). However, 
when cultured in primary liquid cultures for 14 d in the pres- 
ence of combinations of multiple early acting factors (for a 
review,  see reference 1), the CD342 +  CD38-  cells give rise 
to committed progenitor cells which do form colonies in sec- 
ondary methylcellulose cultures (CFC). To generate secondary 
CFC, CD342+CD38-  require at least the presence of IL-3, 
KL, and either IL-1, IL-6, or G-CSF in the primary liquid 
cultures (Fig.  1). No secondary CFC were generated in the 
absence of either IL-3 (not shown) or KL (Fig.  1), and only 
few secondary CFC were produced in the presence of IL-3 
and KL without any other synergistic factors in the primary 
liquid cultures (Fig. 1). The secondary colonies generated from 
CD342+CD38 -  cells  were mostly myeloid with <2%  of 
erythroid or mixed erythroid/myeloid colonies. Most of the 
myeloid colonies consisted of large macrophages. Addition 
of epo to the primary cultures had no effect on the number 
nor on the morphology of the secondary colonies (not shown). 
When the secondary cultures were scored at day 21, secondary 
high proliferative potential CFC (HPP-CFC, defined as mac- 
roscopic colonies of >2 mm diameter with a dense center, 
consisting mostly of large macrophage-like cells) were noted 
(see Fig. 3). These HPP-CFC are believed to arise from more 
primitive progenitor cells than other colony types (13,  14). 
IFN-y  Inhibits  the  Proliferation  and  Differentiation  of 
CD342+CD38 -  Cells.  When IFN-3, was added to the pri- 
mary liquid cultures of CD342 +  CD38- cells (100 cells/well) 
stimulated by cytokine combinations that induce prolifera- 
tion of CD342+ CD38-  cells (see Fig.  1), cell proliferation, 
generation of secondary CFC, and of secondary HPP-CFC 
were profoundly inhibited in a dose-dependent way, with near 
complete inhibition occurring at 5,000 U/ml (Figs.  2 and 
3). The inhibitory effect of IFN-3, was less pronounced, but 
still statistically significant, in cultures stimulated by IL-3 +KL 
(Fig. 2). The inhibitory effect of IFN-y was blocked by adding 
neutralizing antibodies to human IFN-'y to the cultures (Fig. 
3), but not by adding isotype-matched irrelevant control an- 
tibodies. 
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Figure 1.  Effect  of  primary  culture  conditions  of  purified 
CD342 § CD38- bone marrow cells (cytokine combinations mentioned on 
the y-axis) on the generation of secondary CFC. Results expressed as the 
number of secondary CFC/100 CD342+CD38-  cells (mean  +  SEM). 
The number of independent experiments is indicated on the right hand 
side of the figure (n). 
Figure 3.  Dose response curve of the effect of IFN-'y (A), IFN-3/  + 
neutralizing anti-IFN-',/antibody  (O), and IFN-3" +  irrelevant control 
antibody (O) on the primary liquid culture total cell number (left), number 
of day 14 secondary CFC (middle), and day 21 secondary HPP-CFC (right) 
after 14 d of primary liquid culture of CD342+CD38- cells with IL-1, 
IL-6, IL-3, and KL. Results (mean  +  SEM) are expressed as percentage 
of inhibition, compared with primary cultures without IFN-% The number 
of cells after 14 d of primary culture without IFN-3~  was 1,318 _+  354, 
the number of day 14 secondary CFC 473  +  64, and the number of day 
21 secondary HPP-CFC was 61  _+  10 per input of 100 CD342+CD38 - 
cells (pooled results of five independent experiments performed in duplicate). 
To see whether this inhibition was a direct effect of IFN-% 
primary liquid cultures were performed at a single cell level, 
by sorting CD342*CD38 -  cells at one cell/well in 96-well 
plates  in the presence  of IL-3, IL-1, IL-6, and KL with or 
without IFN-3'. The wells in which growth had occurred 
as assessed by microscopic evaluation (primary colonies) were 
picked up, washed, and plated individually in methylcellu- 
lose cultures supplemented with IL-3, GM-CSF, G-CSF, and 
epo. In these single cell culture experiments, the presence of 
iFN-3~ in the primary cultures inhibited the total number 
of secondary CFC to the same extent as in experiments where 
CD342+CD38 -  cells were cultured at 100 cells/well (-67.5 
_+  13.7% vs.  -69.1  +_  4.3%, respectively,  at a concentra- 
tion of 1,000 U/ml, n  =  4), demonstrating that the inhibi- 
tory effect of IFN-3' on the proliferation of CD342 +  CD38- 
cells is a direct one. IFN-3~ primarily inhibited the number 
of CD342+CD38 -  cells forming primary colonies (Table 1, 
top), whereas the number of secondary CFCs per individual 
primary colony was inhibited to  a lesser  extent  (Table  1, 
bottom). 
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Figure 2.  Relative inhibition  induced by IFN-"/(1,000 U/ml) in the 
14-d primary liquid cultures of CD342+ CD38-  cells, supported by the 
cytokine combinations  mentioned on the y-axis, on the generation of sec- 
ondary colonies (results expressed as mean -+ SEM). The number of inde- 
pendent experiments is indicated on the right hand side of the figure (n). 
The IFN-3~-induced inhibition  was statistically significant in all cases (p 
<0.05, Student's t test for paired samples). 
IFN-'f  Does  Not  Inhibit  More  Mature  CD34+CD38 + 
Cells.  The same single cell culture experiments were per- 
formed  using  CD34+CD38 §  bone  marrow  cells,  which 
constitute the remainder of CD34 §  cells (Table  1).  Strik- 
ingly, only 6.7  _+  2.5% of the primary colonies generated 
from this population in the presence of IL-3, IL-1, IL-6, and 
KL contained secondary CFCs (compared with 95.3  _+ 2.4% 
of the primary colonies derived from CD342 +  CD38-  cells, 
/~  =  0.0001).  This indicates that this culture system allows 
a  very  sharp  functional  distinction  of  very  primitive 
CD342+CD38 -  cells  from  more  mature  CD34+CD38 + 
cells. In contrast to the effects of IFN-y on CD342 +  CD38- 
cells,  addition  of IFN-y  to  primary  cultures  of CD34 + 
CD38 + cells had no effect on the number of primary colo- 
nies nor on the number of secondary CFC (Table 1). Moreover, 
IFN-y did not inhibit colony formation in single cell methyl- 
cellulose cultures of CD34+CD38 + cells supported by epo, 
IL-1, IL-6, KL, and IL-3 (mean cloning e~ciency 30.8  -+ 
2.6% without and 27.5  +  3.2% with IFN-qr at 103 U/ml 
respectively,  n  =  6, p  =  0.35). Taken together, these data 
indicate that IFN-'r acts as a highly selective and direct in- 
hibitor of the proliferation and differentiation of very primi- 
tive  CD342+CD38 -  cells  and  not  of  more  mature 
CD34 +  CD38 + cells. 
IFN-  7  Stimulates the Survival of CD342+CD38 -  Cells.  To 
see whether preincubation of CD342+CD38 -  cells in IFN-3r 
also affects their subsequent capacity to generate secondary 
CFC, CD34  z  +  CD38-  cells where first cultured for 4 d ei- 
ther in culture medium (IMDM,  10%  FCS)  or in culture 
medium containing IFN-3,, after which the cells were washed 
and a pre-CFC assay was performed as described above. When, 
after 4 d of preculture in either medium without cytokines 
or  medium containing IFN-3'  (103 U/ml)  the  cells  were 
washed and cultured for another 14 d in the presence of IL-3, 
KL, IL-6, and IL-1, significantly more secondary CFC were 
recovered  from the ceils that had been precultured for 4 d 
in the presence of IFN-3~ than in the absence of IFN-3~ (mean 
difference  +117  _+  26%, p  =  0.02, n  =  4).  This effect is 
due to a survival-enhancing effect of IFN-% since significantly 
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No  IFN-3' 
IFN-3'  103 U/ml  Mean A*  n*  ps 
Percentage of primary colonies in single cell liquid cultures supported by IL-1, IL-6, IL-3, and KL 
CD342+CD38 -  25.4  _+  2.9  13.3  _+  2.7  -48.4  _+  6.7%  6  0.0008 
CD34+CD38 §  22.6  _+  3.1  22.0  _+  3.3  + 1.8  _+  8.0%  6  0.83 
Number  of secondary CFC per individual primary colony 
CD342+CD38 -  73.4  _+  13.1  53.0  +  18.1  -20.0  _+  5.3  4  0.033 
CD34§  §  0.7  _+  0.4  0.2  +  0.2  -0.5  _+  0.4  6  0.31 
* Mean difference  (A) expressed as relative difference  in terms of percentage compared with cultures without IFN-% 
r Number of independent experiments. 
S  Statistics used Student's t test for paired samples. 
more morphologically intact cells, as determined by counting 
the cells in the culture wells by phase contrast microscopy, 
were recovered  after 4 d  of culture with IFN-3' than after 
4 d of culture in medium without cytokines (68.5  +  2.9% 
and 31  _+  4.8%,  respectively,  of the input cell number, p 
=  0.0008, n  =  5, 103 U/ml IFN-3,).  Both the effect on cell 
number  and  on  the  capacity to  generate  secondary CFC 
reached a plateau at an IFN-3~ concentration of 50 U/ml (not 
shown), i.e., at a 2-log lower concentration than the concen- 
tration at  which complete inhibition of proliferation and 
differentiation ofpre-CFC was noted (see Fig. 2). These data 
show that IFN-'y promotes the survival of CD342+CD38 - 
cells and that preincubation in IFN-'y does not inhibit their 
subsequent proliferative capacity. 
Discussion 
The  assay used in  this  report  identifies very primitive 
precursors of CFC, since CD342+CD38 -  cells that do not 
form colonies in semisolid media are stimulated to differen- 
tiate in suspension culture into CFC. CD342 +  CD38-  cells, 
which, according to our data also contain precursors of HPP- 
CFC which are considered to be very early progenitors (13, 
14), are known to be among the most primitive hematopoi- 
etic precursors (8, 9). The fact that in the secondary cultures, 
mostly colonies containing macrophages were recovered might 
indicate that a less primitive cell is detected here.  However, 
many authors have  shown that HPP-CFC  also  consist of 
mostly large macrophage-like cells (13, 14). Moreover and 
in accordance with our data, Lu et al. (15) showed that colo- 
nies with a high replating capacity generated from primitive 
CD343 + cord blood cells consisted mostly of large macro- 
phage-like ceils. The development of  colonies originating from 
very early (stem) cells in these in vitro assays thus seems to 
be biased towards the macrophage lineage. Since this is a two- 
stage culture system, this assay allows the characterization 
of the direct effects of IFN-'y on the early phases of the devel- 
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opment of  primitive progenitor cells (from pre-CFC to CFC), 
without interference of any effects of IFN-y on the terminal 
stages of differentiation (from CFC to mature cell), on which 
IFN-3' has been shown to have stimulatory effects (2-6). 
This report for the first time identifies IFN-3' as a direct 
bidirectional regulator of hematopoiesis whose inhibitory 
effects display a very strong specificity for very primitive pro- 
genitor and stem cells, as evidenced by the direct inhibition 
by IFN-'y of the early stages of proliferation and differentia- 
tion of very primitive CD342 § CD38-  cells, but not of more 
mature CD34+CD38 + cells.  The smaller decrease in sec- 
ondary colony formation induced by IFN-3, in primary cul- 
tures of CD342+CD38-  cells supported by IL-3 +KL (Fig. 
2)  might  be  interpreted  in  the  same  context,  since  the 
CD342 +  CD38-  cells stimulated by this cytokine combina- 
tion are probably less primitive than cells which require a 
combination of three or four cytokines in order to proliferate. 
These effects are moreover undoubtedly direct since they were 
also seen in single cell culture experiments. 
A number of recent reports, including one from our labo- 
ratory (4), demonstrated direct stimulatory effects of IFN-3, 
on human hematopoietic progenitor cells in synergy with 
IL-3 and GM-CSF (2-4). Some reports even suggested that 
IFN-3' has a selective stimulatory effect on more primitive 
progenitors in the murine system (5).  However, in most of 
these reports the effects of IFN-qr on progenitor cells respon- 
sive to single CSF was assessed, indicating that more mature 
progenitor cells were studied. We show in this report that 
IFN-3, does not inhibit, nor stimulate the proliferation and 
differentiation of more mature CD34+CD38 + population 
stimulated by IL-3, IL-1, IL-6, and KL and epo. We could 
thus not confirm the data of Brugger et al. (7) who showed 
that IFN-'y stimulates the expansion of CFC induced by the 
same  four  cytokine combination  using  peripheral  blood 
CD34 + cells. Differences  in target cell populations and pu- 
rity, or in cell isolation procedure and culture could account 
for this discrepancy. Earlier reports showed suppressive effects 
Primitive CD342§  Cells of IFN-3, on committed progenitor ceils (16-18). However, 
in these reports, various crude conditioned media were used 
to stimulate progenitor cell proliferation,  the experiments were 
performed with relatively unpurified bone marrow popula- 
tions and single cell assays were never performed, so that most 
probably indirect  effects were measured. 
Other cytokines that have been identified as negative regu- 
lators of hematopoiesis,  i.e., TGF-B (19-21) and some members 
of the chemokine-family of cytokines, among which macro- 
phage inflammatory protein lot (MIP-lot) (22-24),  tend to 
display a selectivity for the inhibition  of primitive progen- 
itor ceUs, but, in contrast to IFN-3' (2-4), they also inhibit 
committed early human erythroid and myeloid progenitor 
cells responsive to  single  CSF  or to combinations  of two 
growth factors (20-24).  Among the more mature progen- 
itor cells, only the G-CSF-induced proliferation of relatively 
mature progenitors committed to  the neutrophilic  lineage 
is directly inhibited by IFN-3' (4). 
Quite surprisingly, besides inhibiting the growth factor- 
induced proliferation  of CD342+CD38 -  cells,  IFN-3' also 
maintains  their viability in the absence of other cytokines. 
To the best of our knowledge, such a phenomenon has not 
been described for TGF-B  and  MIP-lot.  We have  already 
shown that  IFN-y promotes  the survival of more mature 
human committed erythroid and myeloid progenitor cells (25). 
IFN-3' probably inhibits apoptosis of progenitor cells. How- 
ever,  due to  the very limited  number  of CD34 z+ CD38- 
cells that could be isolated from a bone marrow sample, we 
could not confirm this mechanism by either demonstrating 
a DNA-ladder  or by flow cytometry. 
Since IFN-3' is an inflammatory cytokine that at the same 
time inhibits  proliferation  and cell death of very primitive 
progenitor cells and stimulates proliferation of more mature 
progenitors,  it might, in situations of increased demand for 
blood cells such as infection and inflammation,  stimulate the 
expansion of committed progenitor ceils and their prolifera- 
tion and differentiation into mature cells (2-7), while at the 
same time sparing the cells of the very primitive  stem cell 
compartment from recruitment and thus protecting this com- 
partment from exhaustion. IFN-'y could therefore be useful 
in the setting of chemotherapy for cancer as a stem cell pro- 
tecting agent against cell cycle-specific drugs. Our data fur- 
thermore support the hypothesis that  IFN-y is a candidate 
inhibitor of hematopoiesis in the setting of at least some cases 
of severe aplastic anemia (26). In view of the recent evidence 
that IFN-'y stimulates progenitor cell proliferation (2-7), this 
controversial hypothesis (26, 27) had become less attractive. 
The data presented here however indicate that IFN-'y can in- 
deed inhibit hematopoiesis through a selective and direct effect 
on very primitive  stem cells. 
In conclusion, IFN-3' inhibits the proliferation  of very primi- 
tive  CD342§  -  cells  and  not  of  more  mature 
CD34 +CD38 §  cells  and  is thus a selective hematopoietic 
stem cell inhibitor.  IFN-y, moreover, promotes the survival 
of CD342 +  CD38-  cells. 
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